TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16295040

Group type: EXPERIMENTAL
Intervention: HS-1 (Barrier Cream)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: HS-2 (Barrier Cream)
Number of subjects: 192

Group type: COMPARATOR
Intervention: HP-1 (Skin Care Product)
Number of subjects: 192

Group type: COMPARATOR
Intervention: HP-2 (Skin Care Product)
Number of subjects: 192

Group type: COMPARATOR
Intervention: TEWL measurement for HP-1 vs HS-1
Number of subjects: 192

Group type: COMPARATOR
Intervention: TEWL measurement for HP-2 vs HS-2
Number of subjects: 192
Study: 10756492

Group type: EXPERIMENTAL
Intervention: 1 mg buserelin (BSRL) stimulation (PCOD group P-1, n = 31)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 0.1 mg buserelin (BSRL) stimulation (PCOD group P-0.1, n = 12)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group C-1 (n = 12)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group C-0.1 (n = 11)
Number of subjects: 43
Study: 8951253

Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 9
Study: 1504957

Group type: EXPERIMENTAL
Intervention: Vertical Strip (VS) palpation technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Concentric Circle (CC) palpation technique
Number of subjects: 34
Study: 6388898

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 0.5 to 0.75 mg/kg over 30 to 120 min.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intracoronary rt-PA (after crossover from placebo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (after unresponsive rt-PA treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 45
Study: 31621670

Group type: EXPERIMENTAL
Intervention: Airtraq video laryngoscope
Number of subjects: 70

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 70
Study: 29738412

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (oCEE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (tE2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active treatment (oCEE and tE2 combined)
Number of subjects: 100
Study: 26994987

Group type: EXPERIMENTAL
Intervention: Rabies + JE-Accelerated
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Rabies + JE-Conventional
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Rabies-Conventional
Number of subjects: 661

Group type: COMPARATOR
Intervention: JE-Conventional
Number of subjects: 661
Study: 25265572

Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 32

Group type: COMPARATOR
Intervention: Neutral mood (control)
Number of subjects: 32
Study: 22893265

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 353
Study: 20581041

Group type: EXPERIMENTAL
Intervention: 1SET
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3SET
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1SET and 3SET
Number of subjects: 8
Study: 18076234

Group type: EXPERIMENTAL
Intervention: Linear periodization (n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (n = 10)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Weekly undulating periodization (n = 9)
Number of subjects: 28
Study: 16207768

Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Happy mood
Number of subjects: 0
Study: 12366698

Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) 25 mg (Nemexin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 9665535

Group type: EXPERIMENTAL
Intervention: 3 weeks immobilization
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5 weeks immobilization
Number of subjects: 100
Study: 7641913

Group type: EXPERIMENTAL
Intervention: Low-dose GnRH agonist (GnRH-a) and hMG therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) and hMG therapy
Number of subjects: 70
Study: 2767075

Group type: EXPERIMENTAL
Intervention: Rate-adapted AVD pacing (AVD reduced by 20 ms every 10 beats min-1 from 220 ms at 90 beats min-1 to 100 ms at 150 beats min-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fixed 200 ms AVD
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fixed 150 ms AVD
Number of subjects: 10
Study: 791468

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (long-term therapy)
Number of subjects: 12
Study: 31247674

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 28329366

Group type: EXPERIMENTAL
Intervention: 100% biofeedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Summary feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 25% biofeedback
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 48
Study: 26359441

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 261
Study: 23470183

Group type: EXPERIMENTAL
Intervention: Positive Action program
Number of subjects: 1784
Study: 21272190

Group type: EXPERIMENTAL
Intervention: 6 mg/day MK-0916
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MK-0916 (0.5, 2, or 6 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MK-0916
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19812809

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 74
Study: 18001406

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg daily (EAC group, n = 209)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d. (RAC group, n = 211)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg daily (EAC group)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d. (RAC group)
Number of subjects: 420
Study: 15145166

Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy (CHT-RT) alone (Group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neoadjuvant TPF followed by CHT-RT (Groups 2 and 3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neoadjuvant TPF (Groups 2 and 3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neoadjuvant TPF followed by two cycles of PF during RT (Group 3)
Number of subjects: 24
Study: 11443492

Group type: EXPERIMENTAL
Intervention: Low‐fat, high‐simple carbohydrate diet (SCHO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low‐fat, high‐complex carbohydrate diet (CCHO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Habitual control diet (CD)
Number of subjects: 24
Study: 9219866

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg p.o.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol (30 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betaxolol (20 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8396085

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for three days
Number of subjects: 380

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg bid for ten days
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Azithromycin for sinusitis
Number of subjects: 380

Group type: COMPARATOR
Intervention: Clarithromycin for sinusitis
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Azithromycin for pharyngitis or tonsillitis
Number of subjects: 380

Group type: COMPARATOR
Intervention: Clarithromycin for pharyngitis or tonsillitis
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 380

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 380
Study: 3531845

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31351791

Group type: EXPERIMENTAL
Intervention: Toshiba Aplio MX
Number of subjects: 196

Group type: COMPARATOR
Intervention: GE Vivid E9
Number of subjects: 196

Group type: COMPARATOR
Intervention: Philips EPIQ
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intra- and interobserver repeatability
Number of subjects: 196
Study: 29489037

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 160
Study: 26484794

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of glimepiride and atorvastatin (once daily for 20 weeks)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of glimepiride and atorvastatin
Number of subjects: 427

Group type: COMPARATOR
Intervention: Co-administered glimepiride and atorvastatin (once daily for 20 weeks)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Co-administered glimepiride and atorvastatin
Number of subjects: 427
Study: 24106325

Group type: EXPERIMENTAL
Intervention: Humid‐Heat
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hygrobac
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hygrobac S
Number of subjects: 25
Study: 22251913

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation learning experience
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard teaching methods (discussion, video, low-fidelity methods)
Number of subjects: 28
Study: 20309682

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methylphenidate (20 mg)
Number of subjects: 12
Study: 17686442

Group type: EXPERIMENTAL
Intervention: Cisplatin and pemetrexed combination therapy; standard treatment based on phase III-study evidence; initiation of therapy as early as possible.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumour markers and genomic analysis for early diagnosis; still under investigation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert panel confirmation of histological samples to exclude other tumours; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMIG staging system requiring surgical intervention; no specific intervention details provided.
Number of subjects: 0
Study: 15831613

Group type: EXPERIMENTAL
Intervention: Post-MI heart failure or major LVSD management
Number of subjects: 1
Study: 12741630

Group type: EXPERIMENTAL
Intervention: Abacavir, didanosine, and stavudine
Number of subjects: 60
Study: 10822318

Group type: EXPERIMENTAL
Intervention: Arm ergometry (ARM) at 65% VO2 peak
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Leg ergometry (LEG) at 70% VO2 Peak
Number of subjects: 9
Study: 8865618

Group type: EXPERIMENTAL
Intervention: Unique novel object amidst familiar distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiar target in a display of intermediate set size
Number of subjects: 0
Study: 1729021

Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous heparin administration (1000 U bolus followed by 500 U every 30 minutes)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous heparin administration (1000 U or 1500 U initial bolus followed by continuous heparin infusion)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous heparin administration (1000 U bolus before hip dislocation, and 500 U bolus before femoral canal preparation)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (intraoperative saline)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: All heparin groups combined
Number of subjects: 286
Study: 6488826

Group type: EXPERIMENTAL
Intervention: Double-lumen catheter (DLC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tracheal aspirates
Number of subjects: 27
Study: 3729509

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hard gelatin capsule
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 25
Study: 31310299

Group type: EXPERIMENTAL
Intervention: ICU diary filled in by clinicians and family members (n=355)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Usual ICU care without an ICU diary (n=354)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 709

Group type: COMPARATOR
Intervention: Usual ICU care
Number of subjects: 709
Study: 29138201

Group type: EXPERIMENTAL
Intervention: Iron- and zinc-biofortified pearl millet (FeZn-PM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-biofortified pearl millet
Number of subjects: 200
Study: 25796021

Group type: EXPERIMENTAL
Intervention: Ketamine (Group K)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atropine (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study: 24262040

Group type: EXPERIMENTAL
Intervention: Warfarin (observation group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No anticoagulant or antiplatelet medicine (control group)
Number of subjects: 100
Study: 21396090

Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal pessaries (100mg) for 6 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care (no treatment)
Number of subjects: 98
Study: 18677509

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional haemostatic techniques
Number of subjects: 51
Study: 16599352

Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Normal-weight participants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overweight participants
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal-weight and overweight participants
Number of subjects: 120
Study: 12855212

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral obesity intervention
Number of subjects: 665
Study: 11060719

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (e.g., amprenavir, indinavir, nelfinavir, ritonavir, saquinavir)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparisons between various licensed protease inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparisons of protease inhibitors to other classes of potent antiretroviral drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigations with new protease inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigations of protease inhibitor‐related toxicities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attempts at simplifying current dosing regimens
Number of subjects: 0
Study: 8777207

Group type: EXPERIMENTAL
Intervention: Previous intrapleural procedures (major and minor)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Major previous intrapleural procedures
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with major previous intrapleural procedures
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controls (no previous intrapleural procedures)
Number of subjects: 18
Study: 1390510

Group type: EXPERIMENTAL
Intervention: Vitamin E (E) treated infants
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo (P) treated infants
Number of subjects: 914
Study: 2988769

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no TPN)
Number of subjects: 119
Study: 29966931

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 457

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 457
Study: 27215733

Group type: EXPERIMENTAL
Intervention: web‐based ACT (n = 82)
Number of subjects: 236

Group type: COMPARATOR
Intervention: waiting list (n = 87)
Number of subjects: 236

Group type: COMPARATOR
Intervention: web‐based Expressive Writing (EW; n = 67)
Number of subjects: 236
Study: 24798205

Group type: EXPERIMENTAL
Intervention: Diabetes Education and Self Management for Ongoing and Newly Diagnosed Type 2 diabetes (DESMOND) course delivered by one trained lay educator and one professional educator
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group receiving the standard format DESMOND course delivered by two trained healthcare professional educators
Number of subjects: 260
Study: 22448846

Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 20205074

Group type: EXPERIMENTAL
Intervention: Asenapine (5 or 10 mg BID)
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg QD)
Number of subjects: 1225
Study: 18555147

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with local anesthetics combined with opioids (T(9)-T(10); group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV analgesia with morphine (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall treatment (both groups)
Number of subjects: 40
Study: 16020142

Group type: EXPERIMENTAL
Intervention: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months and 50 mg sildenafil citrate orally on demand
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50 mg sildenafil citrate orally on demand for 6 months only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months
Number of subjects: 30
Study: 12830470

Group type: EXPERIMENTAL
Intervention: Amino acid dialysate (Nutrineal; DAA group, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dextrose dialysate (Dianeal; DD group, n = 30)
Number of subjects: 60
Study: 10426519

Group type: EXPERIMENTAL
Intervention: Focal diencephalic damage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Korsakoff patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frontal lobe pathology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal lobe pathology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frontal lobe and temporal lobe groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right temporal and frontal lobe regions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left temporal region
Number of subjects: 0
Study: 7595137

Group type: EXPERIMENTAL
Intervention: 1 g elemental calcium administered twice daily for 16 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo administered twice daily for 16 weeks
Number of subjects: 32
Study: 2212566

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 382153

Group type: EXPERIMENTAL
Intervention: Domperidone suppositories (30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoclopramide suppositories (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31295335

Group type: EXPERIMENTAL
Intervention: Group antenatal and postnatal care (ANC/PNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional individual model of ANC/PNC
Number of subjects: 0
Study: 29701801

Group type: EXPERIMENTAL
Intervention: Uncontrolled BP (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg)
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Uncontrolled BP in Bangladesh
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Uncontrolled BP in Pakistan
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Uncontrolled BP in Sri Lanka
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Lower wealth index
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Single vs. married
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Higher log urine albumin‐to‐creatinine ratio
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Lower estimated glomerular filtration rate
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Low vs. high adherence to antihypertensive medication
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Pakistan vs. Sri Lanka
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Self‐reported kidney disease
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Receiving vs. not receiving statins
Number of subjects: 1718
Study: 25939394

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Improved corn-soya blend (CSB+)
Number of subjects: 81
Study: 24937648

Group type: EXPERIMENTAL
Intervention: Automated intervention group
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Assisted intervention group
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Navigated intervention group
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Prior CRCS
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Prior CRCS at baseline
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1247
Study: 22433221

Group type: EXPERIMENTAL
Intervention: Docetaxel (DTX) alone, 75 mg/m², 8 cycles, every 3 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Other treatment groups (combined)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Docetaxel (DTX)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Paclitaxel (PTX)
Number of subjects: 300
Study: 19281469

Group type: EXPERIMENTAL
Intervention: tolterodine-ER (4 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 17449504

Group type: EXPERIMENTAL
Intervention: Advice given by pharmacists during consultations
Number of subjects: 0
Study: 15608401

Group type: EXPERIMENTAL
Intervention: Dominant hand of right-handed subjects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-dominant hand of right-handed subjects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dominant hand of left-handed subjects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-dominant hand of left-handed subjects
Number of subjects: 60